Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
View Patent ↗Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
1. A method for treating a disease in a patient, said disease selected from the group consisting of asthma and multiple sclerosis which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (Ia) or (Ib):
wherein:
Ar 1 is pyrimidinyl optionally substituted with 1-3 substituents selected from the group consisting of alkyl, substituted alkyl, amino, substituted amino, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;
R is selected from the group consisting of alkyl, alkoxy, halo, and mono- and dialkyl-amino;
q is an integer from 0 to 2;
R 1 is selected from the group consisting of hydrogen and alkyl;
Y is CH or N;
R 2 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl; and
X is selected from the group consisting of hydroxyl, alkoxy and substituted alkoxy;
or an enantiomer, diastereomer or pharmaceutically acceptable salt thereof;
wherein the compound of Formula I(a) or I(b) has a binding affinity to VLA-4 as expressed by an IC 50 of about 15 μM or less.
2. The method of claim 1 wherein R 1 is hydrogen.
3. The method of claim 2 wherein Y is CH.
4. The method of claim 2 wherein Y is N.
5. The method of claim 3 wherein X is hydroxy.
6. The method of claim 4 wherein X is hydroxy.
7. The method of claim 5 wherein q is zero.
8. The method of claim 5 wherein q is one and R is alkoxy.
9. The method of claim 6 wherein q is zero.
10. The method of claim 6 wherein q is one and R is alkoxy.
11. A method for treating a disease in a patient, said disease selected from the group consisting of inflammatory bowel disease, ulcerative colitis, and Crohn's disease which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (Ia) or (Ib):
wherein:
Ar 1 is pyrimidinyl optionally substituted with 1-3 substituents selected from the group consisting of alkyl, substituted alkyl, amino, substituted amino, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;
R is selected from the group consisting of alkyl, alkoxy, halo, and mono- and dialkyl-amino;
q is an integer from 0 to 2;
R 1 is selected from the group consisting of hydrogen and alkyl;
Y is CH or N;
R 2 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl; and
X is selected from the group consisting of hydroxyl, alkoxy and substituted alkoxy;
or an enantiomer, diastereomer or pharmaceutically acceptable salt thereof;
wherein the compound of Formula I(a) or I(b) has a binding affinity to VLA-4 as expressed by an IC 50 of about 15 μM or less.
12. A method for treating rheumatoid arthritis in a patient which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (Ia) or (Ib):
wherein:
Ar 1 is pyrimidinyl optionally substituted with 1-3 substituents selected from the group consisting of alkyl, substituted alkyl, amino, substituted amino, aryl, substituted awl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;
R is selected from the group consisting of alkyl, alkoxy, halo, and mono- and dialkyl-amino;
q is an integer from 0 to 2;
R 1 is selected from the group consisting of hydrogen and alkyl;
Y is CH or N;
R 2 is selected from the group consisting of alkyl, substituted alkyl, awl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl; and
X is selected from the group consisting of hydroxyl, alkoxy and substituted alkoxy;
or an enantiomer, diastereomer or pharmaceutically acceptable salt thereof;
wherein the compound of Formula I(a) or I(b) has a binding affinity to VLA-4 as expressed by an IC 50 of about 15 μM or less.